Researchers investigate the expression of PARP1 in leukemias with BCR::ABL1 p190+ translocation, finding differential expression in ALL, AML, and CML but no significant correlation with clinical ...
A new study of patients with chronic myeloid leukemia (CML) provides BCR-ABL1 transcript levels at time points within the first year of therapy that can best predict the achievement of a deep ...
Figure 1: ABL001 is an allosteric inhibitor of BCR–ABL1 that selectively inhibits growth of BCR–ABL1-driven cells. Figure 2: ABL001 has a resistance profile that is distinct from catalytic-site ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback